Bharat Biotech has emphasized the safety of its Covaxin Covid vaccine, stating that it has shown excellent safety records with no vaccine-associated incidents such as blood clots or other serious side effects. The company highlighted that Covaxin was developed with a focus on safety first, followed by efficacy. It mentioned that Covaxin was extensively evaluated in more than 27,000 subjects during its licensure process and has been continuously monitored for safety by the health ministry.
Experts say the rare reaction called Thrombosis with Thrombocytopenia Syndrome (TTS) can manifest as clotting at unusual sites and sometimes with hemorrhage. Besides, it is not a concern for people who had taken the vaccine a few years ago. Some people are confusing this with sudden cardiac deaths, which is a completely different topic, they explained
Pointing out that over 100 crore doses of Covishield have been supplied in India and many other countries, Serum Institute of India on Monday sought regular marketing approval for the COVID-19 vaccine, which is currently authorized for emergency use in the country, official sources said.
The row between India and UK over travel norms stems from the Indian government's efforts to get the UK to recognise Covishield as a legitimate vaccine